drugset / Trial / NCT07312630
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
Timeline
- Start
- 2025-09-25
- Primary completion
- 2026-09-25
- Completion
- 2027-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LV009 Injection Infusion | Cell therapy | 0.3 unknown | — |
| Subject | LV009 Injection Infusion | Cell therapy | 0.6 unknown | — |
| Subject | LV009 Injection Infusion | Cell therapy | 1.2 unknown | — |
| Subject | LV009 Injection Infusion | Cell therapy | 2.4 unknown | — |